Wall Street Zen Upgrades Takeda Pharmaceutical (NYSE:TAK) to Buy

Takeda Pharmaceutical (NYSE:TAK) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday.

Other analysts also recently issued research reports about the company. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Finally, Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

NYSE TAK opened at $17.15 on Friday. Takeda Pharmaceutical has a 12 month low of $12.99 and a 12 month high of $18.90. The firm has a market capitalization of $54.96 billion, a PE ratio of 43.98 and a beta of -0.07. The company’s 50 day simple moving average is $16.12 and its 200 day simple moving average is $16.98. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. As a group, equities research analysts forecast that Takeda Pharmaceutical will post 1.12 EPS for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

A number of large investors have recently added to or reduced their stakes in TAK. Capital Research Global Investors increased its holdings in shares of Takeda Pharmaceutical by 0.6% in the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after buying an additional 82,643 shares in the last quarter. UBS Group AG boosted its stake in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after acquiring an additional 2,854,069 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after acquiring an additional 692,404 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after acquiring an additional 370,800 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.